Provided is the use of a glycoengineered antibody for the preparation of a pharmaceutical composition for the treatment of: i) cancer ii) autoimmune thrombocytopenia in chronic graft-versus-host disease or iii) immune-mediated, acquired pure red cell aplasia wherein said antibody specifically binds the human CD20 antigen, wherein said antibody has a decreased proportion of non-bisected complex oligosaccharides having the m/z value of 1648 Daltons and an increased proportion of bisected hybrid and galactosylated complex oligosaccharides having the m/z values of 1664, 1810, and 1826 Daltons relative to a corresponding, non-glycoengineered anti-CD20 antibody, and wherein said antibody reaches the maximal ADCC activity of Mabthera at an antibody concentration that is approximately five to 10-fold lower as a result of said glycoengineering.
